EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA ensures 'Alz1' supply for the EU market 
 
06-Dec-2020 / 22:01 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*IGEA ensures 'Alz1' supply for the EU market* 
 
Hoofddorp, the Netherlands, 6 December 2020. IGEA Pharma N.V. (SIX: IGPH) 
today announced the signature of an agreement with CSM Europe for the 'CE' 
compliant supply of Alz1. The distribution of Alz1 on a wholesale basis in 
selected EU markets is expected to start within the first half of 2021. 
 
*** 
 
*About IGEA* 
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. 
Health-tech products are exclusively preventative. IGEA commercializes an 
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit 
to measure non-bound copper in the blood and a natural dietary supplement 
branded 'Alz1 Tab' designed to reduce blood heavy metals content), and 
intends to launch a diabetes type II prevention set in 2020. 
Non-ceruloplasmin bound copper is an expected Alzheimer's and diabetes type 
II associated biomarker. Controlling non-bound copper can contribute to 
reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore 
commercializes a COVID-19 rapid test for the detection of IgM and IgG 
SARS-CoV-2 related antibodies. Med-tech products focuses on selected 
solutions and specialities. IGEA commercializes dry aerosol generators for 
air and inanimate environmental surfaces sanitization and air sterilization 
and purification devices. 
 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered 
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl [1] 
 
*Contacts* 
Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com 
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.com 
 
*Disclaimer* 
This document constitutes neither an offer to buy nor to subscribe 
securities and neither this document nor any part of it should form the 
basis of any investment decision in IGEA. The information contained in this 
press release has been carefully prepared. However, IGEA bears and assumes 
no liability of whatever kind for the correctness and completeness of the 
information provided herein. IGEA does not assume an obligation of whatever 
kind to update or correct information contained in this press release 
whether as a result of new information, future events or for other reasons. 
This publication may contain specific forward-looking statements and 
assessments or intentions concerning IGEA and its business. Such 
forward-looking statements are subject to known and unknown risks, 
uncertainties and other factors which may result in a substantial divergence 
between the actual results, financial situation, development or performance 
of IGEA and those explicitly or implicitly presumed in these statements. 
Against the background of these uncertainties, readers should not rely on 
forward-looking statements. IGEA assumes no responsibility to update forward 
looking statements or to adapt them to future events or developments, except 
as may be required by law. 
 
Additional features: 
 
File: 20201206 igea nv_press release [2] 
End of ad hoc announcement 
Language:    English 
Company:     IGEA Pharma N.V. 
             Siriusdreef 17 
             2123 WT Hoofddorp 
             Netherlands 
Phone:       +31 23 568 9494 
E-mail:      info@igearesearch.com 
Internet:    www.igeapharma.nl 
ISIN:        NL0012768675 
Listed:      SIX Swiss Exchange 
EQS News ID: 1153076 
 
End of Announcement EQS Group News Service 
 
1153076 06-Dec-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=af89b23b8e443edad67216a4407326b3&application_id=1153076&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=20df440ced4d7841c87f5e060ec4e836&application_id=1153076&site_id=vwd&application_name=news

(END) Dow Jones Newswires

December 06, 2020 16:01 ET (21:01 GMT)